UCLA scientists engineer ready-to-use cancer-fighting T cells for solid tumors
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Oct-2026 23:16 ET (23-Oct-2026 03:16 GMT/UTC)
UCLA researchers have developed a way to mass-produce cancer-fighting T cells from blood stem cells found in cord blood, engineered to target a protein found in many solid tumors — creating uniform batches instead of custom treatments for each patient.
Scientists from University of Galway have uncovered a surprising link between commonly used anti-cancer drugs and antibiotics that could offer a potential new approach to tackling notorious superbug infections.
New study identifies hundreds of previously overlooked micropeptides linked to cancer progression. Hebrew University researchers have discovered that long non-coding RNAs (lncRNAs)—genetic material once thought not to produce proteins—can encode hundreds of tiny proteins collectively called micropeptides. By analyzing nearly 10,000 tumours across 17 cancer types, the team identified hundreds of micropeptides associated with different stages of cancer progression, revealing a previously underexplored layer of cancer biology that could improve understanding of how tumours develop and help identify future biomarkers.
Digital pathology relies on high-resolution imaging for accurate cancer diagnosis, yet high-magnification systems remain slow and costly for large-scale screening. Meanwhile, standard AI super-resolution often generates hallucinated cellular artifacts that risk diagnostic accuracy. To overcome this, researchers developed a hybrid bright-dark field computational framework using fast LED illumination to provide physical guidance. This physics-guided approach doubles spatial resolution, reduces reconstruction artifacts by 84%, and boosts AI cancer screening sensitivity by 11.14%.
On 05 – 06 November 2026, the Josep Carreras Leukaemia Research Institute will host its 2026 Scientific Symposium: "Immunity in Haematological Malignancies: From Molecular Mechanisms to Transformative Therapies". Held at the headquarters of the Institute in Badalona, Barcelona, the Symposium will foster scientific exchange and collaboration to accelerate the translation of discoveries into new treatments for patients with blood cancers.
A new technology that could overcome these barriers, enabling antibodies to reach the most important targets, those located inside the cell itself.